Effect of gonadotropin-releasing hormone analogue treatment in improving final adult height of children with central precocious puberty or early and fast puberty: a Meta analysis
CHU Zhao-Le, JIANG Hui, WU Qian
Department of Pediatrics, Tongcheng People's Hospital of Anhui Province, Tongcheng, Anhui 231400, China
Abstract：Objective To systematically evaluate the effect of gonadotropin-releasing hormone analogue (GnRHa) treatment on the final adult height of children over 6 years of age with central precocious puberty (CPP) or early and fast puberty (EFP). Methods PubMed, MEDLINE, Embase, Cochrane Library, CNKI, and Wanfang Data were searched for related articles on GnRHa treatment for children with CPP or EFP. Stata 12.0 software was used to perform a Meta analysis of related data. Results A total of 10 studies were included, and the total sample size was 720 children, with 475 children in the GnRHa treatment group and 245 children in the control group. The Meta analysis showed that compared with the control group, the GnRHa treatment group had significantly better final adult height (WMD=3.30, 95%CI: 2.49-4.12, P<0.001), standard deviation score of final adult height (WMD=0.51, 95%CI: 0.29-0.73, P<0.001), and height gain (WMD=2.89, 95%CI: 2.17-3.60, P<0.001). No severe adverse events were reported in these studies. Conclusions GnRHa treatment is safe and effective in improving the final adult height of children over 6 years of age with CPP or EFP. Citation:
CHU Zhao-Le,JIANG Hui,WU Qian. Effect of gonadotropin-releasing hormone analogue treatment in improving final adult height of children with central precocious puberty or early and fast puberty: a Meta analysis[J]. CJCP, 2021, 23(11): 1161-1168.
Partsch CJ, Heger S, Sippell WG. Treatment of central precocious puberty: lessons from a 15 years prospective trial. German Decapeptyl Study Group[J]. J Pediatr Endocrinol Metab, 2000, 13(Suppl 1): 747-758. PMID: 10969917. DOI: 10.1515/jpem.2000.13.s1.747.
Kletter GB, Kelch RP. Clinical review 60: effects of gonadotropin-releasing hormone analog therapy on adult stature in precocious puberty[J]. J Clin Endocrinol Metab, 1994, 79(2): 331-334. PMID: 8045943. DOI: 10.1210/jcem.79.2.8045943.
Lazar L, Meyerovitch J, de Vries L, et al. Treated and untreated women with idiopathic precocious puberty: long-term follow-up and reproductive outcome between the third and fifth decades[J]. Clin Endocrinol (Oxf), 2014, 80(4): 570-576. PMID: 24033561. DOI: 10.1111/cen.12319.
Faienza MF, Brunetti G, Acquafredda A, et al. Metabolic outcomes, bone health, and risk of polycystic ovary syndrome in girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogues[J]. Horm Res Paediatr, 2017, 87(3): 162-169. PMID: 28391271. DOI: 10.1159/000456546.
Kauli R, Galatzer A, Kornreich L, et al. Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the bayley-pinneaumethod[J]. Horm Res, 1997, 47(2): 54-61. PMID: 9030968. DOI: 10.1159/000185432.
Lazar L, Lebenthal Y, Yackobovitch-Gavan M, et al. Treated and untreated women with idiopathic precocious puberty: BMI evolution, metabolic outcome, and general health between third and fifth decades[J]. J Clin Endocrinol Metab, 2015, 100(4): 1445-1451. PMID: 25650898. DOI: 10.1210/jc.2014-3748.
Poomthavorn P, Suphasit R, Mahachoklertwattana P. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment[J]. Gynecol Endocrinol, 2011, 27(8): 524-528. PMID: 21501002. DOI: 10.3109/09513590.2010.507289.
Stasiowska B, Vannelli S, Benso L. Final height in sexually precocious girls after therapy with an intranasal analogue of gonadotrophin-releasing hormone (buserelin)[J]. Horm Res, 1994, 42(3): 81-85. PMID: 7995616. DOI: 10.1159/000184152.
Swaiss HH, Khawaja NM, Farahid OH, et al. Effect of gonadotropin-releasing hormone analogue on final adult height among Jordanian children with precocious puberty[J]. Saudi Med J, 2017, 38(11): 1101-1107. PMID: 29114697. PMCID: PMC5767612. DOI: 10.15537/smj.2017.11.21187.
Pasquino AM, Pucarelli I, Accardo F, et al. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function[J]. J Clin Endocrinol Metab, 2008, 93(1): 190-195. PMID: 17940112. DOI: 10.1210/jc.2007-1216.
Bouvattier C, Coste J, Rodrigue D, et al. Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized long-term pilot study[J]. J Clin Endocrinol Metab, 1999, 84(10): 3575-3578. PMID: 10522998. DOI: 10.1210/jcem.84.10.6032.
Chiavaroli V, Liberati M, D'Antonio F, et al. GNRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome[J]. Eur J Endocrinol, 2010, 163(1): 55-62. PMID: 20356934. DOI: 10.1530/EJE-09-1102.
Sava?-Erdeve ?, ??klar Z, Hac?hamdio?lu B, et al. Gonadotropin-releasing hormone analogue treatment in females with moderately early puberty: no effect on final height[J]. J Clin Res Pediatr Endocrinol, 2016, 8(2): 211-217. PMID: 26758571. PMCID: PMC5096478. DOI: 10.4274/jcrpe.2356.
15 Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions: version 5.1.0[EB/OL]. (2011-03) [2021-08-16]. https://training.cochrane.org/handbook/archive/v5.1/.
S?rensen K, Mouritsen A, Aksglaede L, et al. Recent secular trends in pubertal timing: implications for evaluation and diagnosis of precocious puberty[J]. Horm Res Paediatr, 2012, 77(3): 137-145. PMID: 22508036. DOI: 10.1159/000336325.
Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children[J]. Pediatrics, 2009, 123(4): e752-e762. PMID: 19332438. DOI: 10.1542/peds.2008-1783.
Bangalore Krishna K, Fuqua JS, Rogol AD, et al. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium[J]. Horm Res Paediatr, 2019, 91(6): 357-372. PMID: 31319416. DOI: 10.1159/000501336.
Luo XP, Liang Y, Hou L, et al. Long-term efficacy and safety of gonadotropin-releasing hormone analog treatment in children with idiopathic central precocious puberty: a systematic review and meta-analysis[J]. Clin Endocrinol (Oxf), 2021, 94(5): 786-796. PMID: 33387371. PMCID: PMC8248422. DOI: 10.1111/cen.14410.
Franzini IA, Yamamoto FM, Bolfi F, et al. GnRH analog is ineffective in increasing adult height in girls with puberty onset after 7 years of age: a systematic review and meta-analysis[J]. Eur J Endocrinol, 2018, 179(6): 381-390. PMID: 30324797. DOI: 10.1530/EJE-18-0473.
Fu JF, Zhang JW, Chen RM, et al. Long-term outcomes of treatments for central precocious puberty or early and fast puberty in Chinese girls[J]. J Clin Endocrinol Metab, 2020, 105(3): dgz027. PMID: 31702013. DOI: 10.1210/clinem/dgz027.
Liu S, Liu Q, Cheng X, et al. Effects and safety of combination therapy with gonadotropin-releasing hormone analogue and growth hormone in girls with idiopathic central precocious puberty: a meta-analysis[J]. J Endocrinol Invest, 2016, 39(10): 1167-1178. PMID: 27225286. DOI: 10.1007/s40618-016-0486-9.
Wojniusz S, Callens N, Sütterlin S, et al. Cognitive, emotional, and psychosocial functioning of girls treated with pharmacological puberty blockage for idiopathic central precocious puberty[J]. Front Psychol, 2016, 7: 1053. PMID: 27462292. PMCID: PMC4940404. DOI: 10.3389/fpsyg.2016.01053.
Schoelwer MJ, Donahue KL, Didrick P, et al. One-year follow-up of girls with precocious puberty and their mothers: do psychological assessments change over time or with treatment?[J]. Horm Res Paediatr, 2017, 88(5): 347-353. PMID: 28926827. PMCID: PMC5808430. DOI: 10.1159/000479688.
